A Randomized, Double-blind, Placebo-controlled, Single-center, Phase I, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
At a glance
- Drugs RPH 104 (Primary)
- Indications Inflammation
- Focus Adverse reactions; First in man
- Sponsors TRPHARM
- 18 Apr 2017 Planned End Date changed from 1 Jun 2016 to 1 Sep 2017.
- 18 Apr 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.